Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2021
May 20, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Apr 19, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S.
Apr 05, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.
Mar 22, 2021
10:00 PM EDT
That, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 4,285,715 shares of common stock of the Company at a public offering price of $5.25 per share, less underwriting discounts and commissions.
Mar 22, 2021
5:18 PM EDT
It has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 1,904,762 shares of common stock of the Company at a public offering price of $5.25 per share, less underwriting discounts and commissions.
Mar 22, 2021
8:30 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S.
Mar 12, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.
Mar 08, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Anixa's Chief Executive Officer, Dr.
Mar 04, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued the first European patent for Anixa's novel CAR-T cancer treatment technology, which has been licensed from The Wistar…
Feb 25, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright Global Life Sciences Conference being held March 9-10 , 2021.
Feb 16, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that animal testing has commenced with two proprietary compounds that have shown potency in in vitro studies.
Jan 13, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at B. Riley's Inaugural Oncology Investor Conference to be held January 20-21 , 2021.
Jan 05, 2021
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14 , 2021.
2020
Dec 21, 2020
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.
Dec 14, 2020
9:00 AM EST
It and partner OntoChem GmbH have verified that one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2.
Dec 01, 2020
9:00 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an innovative ovarian cancer vaccine technology.
Nov 23, 2020
8:30 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.
Oct 27, 2020
8:00 AM EDT
It will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern.
Sep 08, 2020
8:00 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual 2020 H.C.
Jul 28, 2020
9:00 AM EDT
Its prophylactic breast cancer vaccine is making progress towards clinical trials.
